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STATE-OF-THE-ART PAPERASTATE-OF-THE-ART PAPER705Genetics of Hypertrophic CardiomyopathyBarry J. Maron, Martin S. Maron, Christopher Semsarian
Hypertrophic cardiomyopathy (HCM) is the most common familial heart disease with vast
genetic heterogeneity. Mutations in 11 or more genes encoding proteins of the cardiac
sarcomere (1,400 variants) are responsible for, or associated with, HCM. The current power
of HCM mutational analysis, albeit more limited than initially envisioned, lies most
prominently in screening family members at risk for developing disease. Interfacing a
heterogenous disease with the vast genetic variability of the human genome, and high
frequency of novel mutations, has created unforeseen difficulties in translating complex science
(and language) into the clinical arena. Major challenges rest with making reliable distinctions
between pathogenic mutations and benign variants.VIEWPOINT VIEWPOINT
716Rationale for Increased Efforts to Understand the
Pathophysiology of Lp(a) and Develop Targeted TherapiesSotirios Tsimikas, Jennifer L. Hall
Recent published studies have provided increasing evidence that lipoprotein(a) [Lp(a)] may be
a potential causal, genetic, independent risk factor for cardiovascular disease (CVD).
Circulating Lp(a) levels are primarily influenced by the LPA gene without significant dietary
or environmental effects. Recent clinical studies have shown that genetically determined Lp(a)
levels are continuously and linearly related to the risk of CVD, yet the pathophysiology of
Lp(a) is poorly understood and targeted therapies to lower Lp(a) are not available. Tsimikas
and Hall provide a rationale for increased basic and clinical investigational efforts to further
understand Lp(a) pathophysiology and perform studies to assess whether reducing Lp(a) levels
lowers CVD risk.(continued on page A-22)
AUGUST 21, 2012 (continued) A-22CLINICAL RESEARCH CARDIOVASCULAR RISK722Apolipoprotein A Polymorphisms Predict Risk of Systemic Atherosclerotic EventsAnna Helgadottir, Solveig Gretarsdottir, Gudmar Thorleifsson, Hilma Holm, Riyaz S. Patel,
Thorarinn Gudnason, Gregory T. Jones, Andre M. van Rij, Danny J. Eapen, Annette F. Baas,
David-Alexandre Tregouet, Pierre-Emmanuel Morange, Joseph Emmerich, Bengt Lindblad, Anders Gottsäter,
Lambertus A. Kiemeny, Jes S. Lindholt, Natzi Sakalihasan, Robert E. Ferrell, David J. Carey,
James R. Elmore, Philip S. Tsao, Niels Grarup, Torben Jørgensen, Daniel R. Witte,Torben Hansen,
Oluf Pedersen, Roberto Pola, Eleonora Gaetani, Hulda B. Magnadottir, Cisca Wijmenga, Gerard Tromp,
Antti Ronkainen, Ynte M. Ruigrok, Jan D. Blankensteijn, Thomas Mueller, Phil Wells, Javier Corral,
Jose Manuel Soria, Juan Carlos Souto, John F. Peden, Shapour Jalilzadeh, Bongani M. Mayosi,
Bernard Keavney, Rona J. Strawbridge, Maria Sabater-Lleal, Karl Gertow, Damiano Baldassarre,
Kristiina Nyyssönen, Rainer Rauramaa, Andries J. Smit, Elmo Mannarino, Philippe Giral, Elena Tremoli,
Ulf de Faire, Steve E. Humphries, Anders Hamsten, Vilhelmina Haraldsdottir, Isleifur Olafsson,
Magnus K. Magnusson, Nilesh J. Samani, Allan I. Levey, Hugh S. Markus, Konstantinos Kostulas,
Martin Dichgans, Klaus Berger, Gregor Kuhlenbäumer, E. Bernd Ringelstein, Monika Stoll, Udo Seedorf,
Peter M. Rothwell, Janet T. Powell, Helena Kuivaniemi, Pall T. Onundarson, Einar Valdimarsson,
Stefan E. Matthiasson, Daniel F. Gudbjartsson, Guðmundur Thorgeirsson, Arshed A. Quyyumi,
Hugh Watkins, Martin Farrall, Unnur Thorsteinsdottir, Kari Stefansson
Helgadottir and colleagues investigated the effects of genetic variations in the apolipoprotein (a)
gene (LPA) on vascular diseases. Two LPA variants (rs10455872 and rs3798220) were
examined for association with ischemic stroke, peripheral arterial disease (PAD),
abdominal aortic aneurysm (AAA), venous thromboembolism (VTE), coronary artery
disease (CAD), carotid intima media thickness (IMT), and angiographic CAD severity.
The number of positive alleles associated with the risk of ischemic stroke due to large
artery atherosclerosis, PAD, and AAA, but not with the other stroke subtypes. While the
LPA variants did not associate with IMT, they did associate with the number of
obstructed coronary vessels. There was no association of LPA score with VTE. These
findings help to clarify the risk associated with elevated LPA levels.CARDIOVASCULAR RISK730Subclinical Hypothyroidism Linked to Increased Risk of DeathFen-Yu Tseng, Wen-Yuan Lin, Cheng-Chieh Lin, Long-Teng Lee, Tsai-Chung Li, Pei-Kun Sung,
Kuo-Chin Huang
Tseng and colleagues evaluated the relationship between subclinical hypothyroidism (SCH)
and all-cause and cardiovascular disease (CVD) mortality. SCH was defined as an elevated
thyroid-stimulating hormone (TSH) level with a normal thyroxine (T4) level in this review of
100,000 Taiwanese subjects. Compared to subjects with euthyroidism, after adjustment for
age, sex, body mass index, diabetes, hypertension, dyslipidemia, smoking, alcohol consumption,
betel nut chewing, physical activity, income, and education level, the relative risks of
deaths from all-cause and CVD among subjects with SCH were 1.30 and 1.68,
respectively. These findings confirm a link between SCH and CVD death.(continued on page A-23)
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738omparison of New Oral Anticoagulant Drugs for Efficacy
and Safety When Used for Stroke Prevention in Atrial FibrillationGregory Y. H. Lip, Torben Bjerregaard Larsen, Flemming Skjøth, Lars Hvilsted Rasmussen
A “head-to-head” direct comparison of drugs is the preferred method for comparing
treatments, but this is unlikley to occur for some time, if ever, for the recently introduced oral
anticoagulant drugs for the prevention of stroke in patients with atrial fibrillation. Lip and
colleagues instead performed an indirect comparison, using warfarin as a common
comparator. There was a significantly lower risk of stroke and systemic embolism (by 26%)
for dabigatran (150 mg BID) compared to rivaroxaban, but no significant differences between
the other options. Major bleeding was lower with apixaban compared to dabigatran
150 mg BID (by 26%) and rivaroxaban (by 34%), but not significantly different from
dabigatran 110 mg BID. These results, with the limitations of an indirect comparison, may
help to guide the clinician in choosing between the new oral anticoagulants.Editorial Comment: Christopher P. Cannon, Payal Kohli, p. 747HEART RHYTHM DISORDERS
749tatins May Decrease the Risk of Ventricular Tachyarrhythmias
in Patients With NICMJonathan Buber, Ilan Goldenberg, Arthur Moss, Paul J. Wang, Scott McNitt, W. Jackson Hall,
Michael Eldar, Alon Barsheshet, Michael Shechter
Some prior studies have suggested that statins have antiarrhythmic properties. Buber and
colleagues studied the antiarrhythmic potential of statins in patients with nonischemic
cardiomyopathy (NICM) enrolled in MADIT-CRT (Multicenter Automatic Defibrillator
Implantation Trial with Cardiac Resynchronization Therapy). Multivariate analysis showed
that statin therapy was independently associated with a 77% reduction in the risk of fast
ventricular fibrillation/ventricular tachycardia (VT/VF) or death and a 46% reduction in the
risk of appropriate implantable cardioverter-defibrillator shocks. The cumulative probability of
fast VT/VF or death at 4 years was 11% in those treated with statins compared to 19% in
those who were not. These results suggest that statins should be considered in patients with
NICM at risk of life-threatening arrhythmias, but this was not a randomized controlled trial.(continued on page A-24)
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756ynamic 3D Magnetic Resonance Perfusion Imaging Shows High Correlation
With Fractional Flow ReserveRoy Jogiya, Sebastian Kozerke, Geraint Morton, Kalpa De Silva, Simon Redwood, Divaka Perera,
Eike Nagel, Sven Plein
Three-dimensional (3D) myocardial perfusion imaging with cardiovascular magnetic resonance
(CMR) has previously shown good diagnostic accuracy compared to quantitative coronary
angiography (QCA). In this study, Jogiya and colleagues compared 3D CMR to fractional flow
reserve (FFR) measurements. Perfusion was scored on a patient and coronary territory basis.
Sensitivity, specificity, and diagnostic accuracy of CMR for the detection of significant coronary
artery disease (CAD) (FFR 0.75) were 90%, 91 % and 91%, on a patient basis and 79%, 92%
nd 88%, respectively by coronary territory. 3D myocardial perfusion CMR accurately detects
unctionally significant CAD as defined by FFR and provides an assessment of ischemia burden in
greement with the invasively derived Duke Jeopardy Score.ditorial Comment: Jens Vogel-Claussen, p. 766VASCULAR DISEASE768Benefits of Tadalafil for PAH Confirmed to 68 WeeksRonald J. Oudiz, Bruce H. Brundage, Nazzareno Galie‘, Hossein Ardeschir Ghofrani, Gerald Simonneau,
ady T. Botros, Melanie Chan, Anthony Beardsworth, Robyn J. Barst, for the PHIRST Study Group
Tadalafil is an oral phosphodiesterase-5 (PDE-5) inhibitor approved for treatment of pulmonary
arterial hypertension (PAH). In the placebo-controlled, randomized, 16-week PHIRST
(Pulmonary Arterial Hypertension and Response to Tadalafil) study, 40-mg tadalafil improved
exercise capacity and delayed clinical worsening. The PHIRST-2 trial studied the long-term safety
and durability of tadalafil by extending the study for another 52 weeks. The safety profile of
tadalafil in PHIRST-2 was similar to that of PHIRST, with typical PDE-5 inhibitor adverse
events. The improvement in 6 min walk distance achieved in PHIRST was maintained at
PHIRST-2 completion. Long-term treatment with tadalafil was well tolerated and the benefits
attained at 16 weeks appear to be sustained for the long term.VASCULAR DISEASE
775xpression of the Pro-Inflammatory Protein S100A12
Linked to Risk of TAA DissectionDeepanjana Das, Joseph Gawdzik, Lisa Dellefave-Castillo, Elizabeth M. McNally, Aliya Husain,
Jai Raman, Marion A. Hofmann Bowman
Das and colleagues recently reported that transgenic mice engineered to express human S100A12,
a pro-inflammatory protein, in aortic smooth muscle cells develop thoracic aortic aneurysms
(TAA). In this paper, they examine S100A12 expression in human aortic diseases using biopsy
samples obtained from patients presenting with TAA, either with dissection or for elective repair.
There was a strong expression of S100A12 in inflammatory cells and in smooth muscle cells in all
cases of thoracic aneurysms with type A dissection, and in approximately 25% of clinically stable
TAA. Studies on cultured human aortic smooth muscle cells show a direct role of S100A12 in
mediating apoptosis. Together these data demonstrate that S100A12 is up-regulated in TAAD
and may contribute to the pathogenesis of TAAD.
